The Center for Excellence in Engineering Biology has awarded a $500,000 grant to Columbia University to develop human cells that can grow with reduced external nutrients, known as prototrophy. This pilot project is part of the Genome Project-write (GP-write) Grand Challenge, aiming to deepen an understanding of life and develop pragmat...
New technologies can assist in protecting older adults from financial fraud, including transactions via wearable technologies and bank cards with chip-and-signature security features. Professionals should be trained to recognize signs of cognitive decline and help clients plan for the possibility of future impairment.
Four recent studies found companies with best-in-class workplace health programs outperformed the Standard & Poor's index by 7-16 percent per year. Employers investing in employee health can see a positive impact on their bottom line.
A comprehensive analysis found that the NIH spends only 7-9% of its budget on behavioral interventions to prevent NCDs, despite 70% of US deaths being due to these diseases. Increasing funding for prevention research could save lives and reduce healthcare costs.
The Multiple Myeloma Research Foundation has made landmark genomic and clinical data from the CoMMpass Study available to researchers via the MMRF's Researcher Gateway. This data includes patient-level biomarker and clinical data, genomic information, and treatment responses, offering new avenues for research into multiple myeloma.
A new study recommends five steps for businesses and Americans to benefit from workplace disease prevention programs. The program could positively influence the health of 155 million working-age Americans while financially benefiting their employers by reducing healthcare costs.
A new JACS paper demonstrates continuous and controlled translocation of a single-stranded DNA polymer through a protein nanopore using a DNA polymerase enzyme. This achievement advances the development of Strand Sequencing using nanopores, a crucial component of molecular motors.
Researchers at UCSC and Oxford Nanopore Technologies Ltd demonstrate fine control of DNA translocation through a protein nanopore using electronic feedback. This breakthrough advances towards direct, electrical detection and analysis of single molecules for various applications, including DNA sequencing.
The OxiNet III system enhances patient safety by continuously monitoring oxygen saturation levels remotely. This technology is integrated into over 450 US hospitals and supports safe care for critically ill patients.
The Florida Department of Health has approved the use of Cyanokit 5g, a hydroxocobalamin injection, in emergency medical services (EMS) and fire vehicles. This treatment is intended to help first responders quickly respond to suspected cases of cyanide poisoning at the scene of an accident.
A clinical trial found that combining nebulized formoterol fumarate with tiotropium significantly improves dyspnea, COPD symptoms, and rescue medication use. The treatment also shows promise in relieving shortness of breath, chest tightness, and nighttime awakenings.
A study found that combining nebulized formoterol fumarate with tiotropium significantly improved COPD symptoms, including shortness of breath and chest tightness, in patients. The treatment also showed enhanced control of COPD symptoms, with decreased use of albuterol rescue medication.
The study shows that Perforomist Inhalation Solution delivers bronchodilation comparable to DPI delivery and has similar linear kinetics and excreted drug levels. This offers an effective, long-term treatment option for patients with COPD who may have difficulty coordinating other devices.
Concomitant use of nebulized formoterol fumarate and tiotropium shows improved bronchodilation in COPD patients, with fewer adverse events. The study demonstrated significant improvements in lung function and clinical outcomes for COPD patients with moderate to severe disease manifestations.
Two clinical trials demonstrated that Perforomist Inhalation Solution is a safe and effective treatment for moderate-to-severe COPD. The studies found no significant increases in cardiovascular events or adverse effects, making it a welcome addition to the physician's arsenal.
The clinical trial data show that Perforomist Inhalation Solution provides rapid bronchodilation, improves lung function, and enhances patient quality of life compared to placebo. The treatment also has a favorable safety profile and is well-tolerated.
The FDA-approved Perforomist Inhalation Solution is a long-acting bronchodilator that improves the quality of life for COPD patients. The solution was shown to be effective in treating chronic obstructive pulmonary disease (COPD) symptoms and improving lung function.
A large multiyear database analysis shows that Curosurf (poractant alfa) Intratracheal Suspension significantly improves neonatal survival in preterm infants with RDS. The study found nearly 20% lower death rates for babies treated with poractant alfa compared to beractant or calfactant.
CYC202 demonstrates significant cancer cell death, with 54% of patients testing positive for apoptosis following single agent treatment. Seven patients experienced long-lasting tumour stabilisation in Phase I trials, showcasing potential for selective treatment based on genetic profiles.
Researchers at Cyclis Pharmaceuticals have discovered a new mechanism for treating cancer, involving the activation of the E2F1 protein with small molecule drugs. The findings, published in the Proceedings of the National Academy of Sciences, show that this approach can selectively kill cancer cells while sparing normal cells.
The study found patients who received the high-dose regimen had significantly longer overall and disease-free survival rates than those who received a lower dose. The company plans to initiate a Phase III trial of GVAX prostate cancer vaccine in the first half of 2003.
The NCCN has released new guidelines to address cancer-related fatigue and treatment-related anemia in cancer patients. The guidelines provide a framework for clinicians to assess and treat these conditions, with a focus on symptom management and improving patient outcomes.
Researchers at Genetica and Cold Spring Harbor Laboratory have developed a cost-effective method for determining the role of specific genes using RNAi. This approach enables stable silencing of gene expression in mammalian cells, allowing for rapid assessment of gene function, previously limited to plants and certain model organisms.
The RNA Invader assay directly detects gene expression levels without sample contamination, allowing for accurate quantification of small changes in biologically significant genes. This technology also discriminates between nearly identical RNA sequences, enabling researchers to identify specific targets with consistency.
The RNA Invader assay directly detects gene expression levels from crude cell samples, eliminating costly and time-consuming steps. This technology allows for precise quantification of small changes in biologically significant genes.
MARstem demonstrates potential as a multilineage hematopoietic therapy to treat or prevent pancytopenia following chemotherapy in breast cancer patients. The study's results show excellent safety and preliminary efficacy, suggesting MARstem may improve debilitating side effects of cancer treatment.
Researchers at ZymoGenetics have identified a novel Interleukin, IL-21, and its receptor, which play a crucial role in regulating the immune system. The discovery was made using an integrated genomics approach and has shown promising results in promoting the activation of immune cells.
Vascugel, a perivascular tissue engineered implant, prevents intimal hyperplasia by regulating biochemical compounds involved in blood vessel repair. The study supports the potential use of Vascugel to enhance cardiovascular procedures and reduce costs associated with (re)stenosis.
Researchers at UroGenesys identify a novel cell-surface antigen called STEAP, expressed on prostate cancers but rarely in non-prostate tissues. The discovery suggests STEAP may be a promising target for new treatments and diagnostic tools to monitor prostate cancer progression.